Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promisestocktwits.comTraders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.
Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metserainvestors.comNovo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera.
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'benzinga.comNovo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and potential legal action.
The market is filled with gapping stocks in Thursday's session.chartmill.comToday's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
2 High-Yield Stocks With Fresh Catalystsfool.comIncome investors can capture yields above 5% from companies executing business transformations.
2 Mega-Dividend Stocks With Yields As High As 7%fool.comDividend stocks with high yields can be great investment opportunities, but those yields can also be red flags.
Down 44%, Should You Buy the Dip on Viking Therapeutics?fool.comThe company is readying to take on pharma giants Novo Nordisk and Eli Lilly.
Where Will Pfizer Be in 5 Years?fool.comPfizer is working hard to deal with some big headwinds it has coming up, but in five years, this should all be in the past.
Down 50%, Should You Buy the Dip on Pfizer?fool.comPfizer's stock price is down materially from its 2021 highs, but it is also up notably from its April 2025 lows.
3 Reasons to Buy Pfizer Stock Nowfool.comAfter years of underperformance, the future is looking brighter for the drugmaker.
3 Things You Need to Know if You Buy Pfizer Todayfool.comPfizer has an attractive 7.2% dividend yield, but there are some pros and cons you need to understand before you buy it.
Got $200? 2 Healthcare Stocks to Buy and Hold Foreverfool.comThese stocks could see growth take off over the next few years.
Metsera Reports Up To 14% Weight Loss In Phase 2b Obesity Trialbenzinga.comMetsera's MET-097i cut weight up to 14% in Phase 2b trials, with manageable side effects, as the company targets a global Phase 3 program in 2025.
Pfizer Just Reminded Investors Why You Should Never Count Its Stock Outfool.comThe company recently announced an acquisition that will bolster its growth prospects in the GLP-1 obesity market.
3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Incomefool.comRight now, these dividend payers are top options for folks who like to set it and forget it.
